dennis mccain
  • Home
  • Investing
    • Best Ideas
    • New Highs
    • Dividend Increases
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options
  • Photography
    • Photography Gear
    • Hiking Trails
  • Biography
  • Index
  • Contact Me

Investing

Ideas and Strategies on Investing.

Previous Articles

Idera Pharmaceuticals

10/11/2017

2 Comments

 
Idera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on oncology and rare diseases. The Company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: (1) Toll-like receptor, or TLR, targeting technology and (2) our third-generation antisense, or 3GA, technology. They developed these platforms based on scientific expertise and pioneering work with synthetic oligonucleotides.

Using TLR targeting technology the Company designs synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. Using their 3GA technology they are developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera believes that 3GA technology may potentially reduce the immunotoxicity and increase the potency of earlier generation antisense and RNA interference, or RNAi, technologies.


The Company's business strategy is focused on the clinical development of drug candidates for oncology and rare diseases characterized by small, well-defined patient populations with serious unmet medical needs. Idera believes they can develop and commercialize these targeted therapies on their own. To the extent they seek to develop drug candidates for broader disease indications, they explore potential collaborative alliances. 

I'm extremely attracted to this company's revenue growth and its liability coverage, but little else is available for determining this company's potential going 
forward. So with so little to go on fundamentally, I rely heavily on the price chart. On the chart it can easily be seen that there's a little resistance at four, five and six dollars per share but after that there's pretty much clear skies. 

So with individual shares being this inexpensive, I'll pick up a couple hundred shares and see what happens. This stock could easily double or triple over the next year. Or it could be just another mistake and learning experience.


Picture

​Idera Pharmaceuticals
, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company's drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. It also develops IDRA-008 for undisclosed liver target for rare disorder; 3GA compound for renal target; and IMO-9200, a drug candidate for potential use in selected autoimmune disease indications. In addition, the company is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GSK to research, develop, and commercialize selected molecules from its 3GA technology for the treatment of selected targets in renal disease; collaboration with Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

(Summary) (Company) (Chart)
11 October 2017
Price $2.77
1yr Target $5.75
Analysts 4
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 107.58%
Yield 0.00%
1yr Tot Return 107.58%

P/E ---
PEG ---
Beta 2.14


EPS (ttm) $-0.35
EPS next yr $-0.50
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $376.08 Mil
Revenues $16.20 Mil
Earnings $-48.60 Mil
Profit Margin ---

Quick Ratio 11.10
Current Ratio 11.10
Debt/Equity 0.01


1yr RevGR 6405.62%
3yr RevGR 587.60%
5yr RevGR 214.08%

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -55.10%
ROE -61.10%


2 Comments
DP Bouffard
10/25/2017 05:32:12 am

With the October 25th news about an offering we are now far from the target you set. It seems that a lot of people knew in advance. There was so much selling in the last days, along with heavy downside.

Reply
Dennis link
10/25/2017 09:08:11 am

I agree. It’s a real gut punch. Apparently news still leaks among insiders. I’ll use the opportunity to load up on the shares sub-$2.

Reply



Leave a Reply.

    Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

    Picture

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.


    RSS Feed


    Picture
    Top 100 Blogs for Dividend Investors

    Picture
    Follow Me on StockTwits!



    Dividend Growth Stocks
    Dividend Growth Investor


    Picture
    I'm on Seeking Alpha too!

    Archives

    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013


    ADDITIONAL RESOURCES:
    4 Month INDU Chart
    Dividend Ex-Dates
    Bidness Etc
    SharpCharts Voyeur
    StockCharts.com

    FINVIZ
    Seeking Alpha
    BDC Reporter
    Roadmap2Retire
    DivHut
    Dividend Growth Investor

    Dividend Yield

    Stock Market Mentor
    Chart Swing Trader
    Dividend Announcements
    IBD TV
    Stocks to Watch Today
    Dividend Detective

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Picture
Powered by Create your own unique website with customizable templates.
✕